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Generating tier 2 HIV-neutralizing antibody (nAb)
responses by immunization remains a challenging
problem, and the immunological barriers to induc-
tion of such responses with Env immunogens remain
unclear. Here, some rhesus monkeys developed
autologous tier 2 nAbs upon HIV Env trimer immuni-
zation (SOSIP.v5.2) whereas others did not. This was
not because HIV Env trimers were immunologically
silent because all monkeys made similar ELISA-
binding antibody responses; the key difference was
nAb versus non-nAb responses. We explored the
immunological barriers to HIV nAb responses by
combining a suite of techniques, including longitudi-
nal lymph node fine needle aspirates. Unexpectedly,
nAb development best correlated with booster im-
munization GC B cell magnitude and Tfh character-
istics of the Env-specific CD4 T cells. Notably, these
factors distinguished between successful and un-
successful antibody responses because GC B cell
frequencies and stoichiometry to GC Tfh cells corre-
lated with nAb development, but did not correlate
with total Env Ab binding titers.
INTRODUCTION
The efficacy of the vast majority of human vaccines is associated
with antibody (Ab) responses (Plotkin, 2010). We still know
critically little about the immunological processes important for
the generation of neutralizing antibodies and how to maximizeCell Repor
This is an open access article under the CC BY-Nsuch responses during immunization (Burton and Hangartner,
2016; Corti and Lanzavecchia, 2013; Crotty, 2014). Induction
of protective antibodies by vaccination is dependent both on
features of the immune system and the immunogen. Although
CD4 T cells and B cell responses are essential, the specific
characteristics of those responses that are responsible for suc-
cessful development of vaccine-elicited neutralizing antibodies
remain poorly characterized for any vaccine. The immunogen
must properly mimic the relevant pathogen structure. Minimal,
if any, neutralizing antibody responses to meaningful clinical
isolate HIV strains (tier 2 or tier 3) have been detected in human
HIV vaccine trials (Mascola and Montefiori, 2010; Sliepen and
Sanders, 2016). The immunogens in those vaccine trials were
HIV Env gp120 monomers, not trimers. Rapid progress has
been made in recent years in the engineering of HIV vaccine im-
munogens. The construction of the BG505 SOSIP.664 trimer
now permits presentation of a recombinant, well ordered HIV-1
Env trimer to the immune system (Julien et al., 2013; Lyumkis
et al., 2013; Sanders et al., 2013). The structure of SOSIP Env
trimer is an accurate reflection of the native membrane-ex-
pressed HIV-1 Env trimer (Lee et al., 2016).
Non-human primates are an important animal model for
testing candidate HIV vaccines because of their evolutionary
relatedness to humans (Hessell and Haigwood, 2015). Although
non-human primate (NHP) HIV protein immunization studies
have been done for over 20 years, significant tier 2 neutralizing
antibody responses in immunized non-human primates have
only been reported in two studies published recently (Hessell
et al., 2016; Sanders et al., 2015). In a first study of four rhe-
sus macaques (RMs) immunized with BG505 SOSIP.664, some
animals developed low levels of autologous tier 2 neutralizing
antibodies whereas, in the same study, BG505 gp120-immu-
nized macaques did not (Sanders et al., 2015). High titers ofts 17, 2195–2209, November 22, 2016 ª 2016 The Author(s). 2195
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
non-neutralizing antibody responses, such as those targeting
the V3 loop tip, were also generated in BG505 SOSIP.664-immu-
nized animals. Competition between Ab responses to ‘‘difficult’’
HIV-neutralizing epitopes and ‘‘easy’’ non-neutralizing Env epi-
topes may limit the generation of neutralizing antibodies (Hu
et al., 2015; Sattentau, 2014).
HIV broadly neutralizing antibodies (bnAbs) are highly somat-
ically mutated, and the mutations are necessary for neutraliza-
tion breadth (Burton and Mascola, 2015; Haynes et al., 2016;
Klein et al., 2013).Mutations occur in germinal center (GC) B cells
during affinity maturation, whereby GC B cells undergo repeated
rounds of somatic hypermutation of their antigen-binding B cell
receptor (BCR) and selection by GC T follicular helper (Tfh)
CD4 T cells (Crotty, 2014; Victora and Nussenzweig, 2012).
Germinal centers occur in lymphoid tissues, such as lymph
nodes, but not in peripheral blood. Consequently, direct studies
of germinal centers have not been possible in HIV bnAb+ individ-
uals. Nevertheless, markers connected to GC activity have been
associated with the generation of HIV bnAbs. A subset of circu-
lating memory Tfh cells correlated with the generation of HIV
bnAbs (Locci et al., 2013). In addition, plasma concentrations
of the chemokine CXCL13 correlated with lymph node GC activ-
ity (Havenar-Daughton et al., 2016a) and were elevated in bnAb+
individuals (Cohen et al., 2014; Havenar-Daughton et al., 2016a).
The importance of GC responses and Tfh cells for the generation
of HIV nAbs is also supported by studies of simian immunodefi-
ciency virus (SIV)-infected macaques (Hong et al., 2014; Petro-
vas et al., 2012; Yamamoto et al., 2015).
Therefore, the data suggest that generation of neutralizing
antibody responses against HIV will likely require an immuniza-
tion regimen that optimizes the induction of GC Tfh cells and
GCs. However, for candidate HIV vaccines, these concepts are
only inferences. Indeed, a recent large NHP vaccine study with
an HIV gp140 immunogen found no association between so-
matic hypermutation (SHM) and HIV Ab responses (Francica
et al., 2015). Little is known about the immunological factors
determining whether or not neutralizing antibody responses
develop in response to Env trimer immunization.
RESULTS
Generation of AutologousHIV-Neutralizing Antibodies in
NHPs Immunized with BG505 SOSIP.v5.2
HIV bnAbs consistently protect NHPs against simian/human
immunodeficiency virus (SHIV) infection in passive transfer
experiments when the circulating neutralizing Ab (nAb) titers
are R 1:100 (Gautam et al., 2016; Moldt et al., 2012; Shingai
et al., 2014), with detectable protection even at titers of 1:20
(Gautam et al., 2016). Immunization of NHPs with a well formed
HIV Env trimer, BG505 SOSIP.664, has not consistently elicited
autologous tier 2 nAbs of substantial magnitude (R1:50 titer).
We immunized a cohort of RMs with a modified BG505 N332
SOSIP designed to improve the stability of the protein (BG505
SOSIP.v5.2; A.T.P. and R.W.S., unpublished data). In addition,
we utilized a modified immunization regimen that included sub-
cutaneous bilateral immunizations, which may engage more B
and CD4 T cells (Figure 1A). Two different adjuvants were tested
in parallel, with groups of eight (PLGA/R848+MPL, ‘‘PLGA’’) and2196 Cell Reports 17, 2195–2209, November 22, 2016four (Iscomatrix) animals. Two weeks after the final immuniza-
tion, serum was tested for autologous tier 2 nAb responses to
BG505 T332N pseudovirus. The majority of immunized animals
(9 of 12, 75%) generated detectable nAb responses (Figures
1B and S1; Table S1). No significant difference was observed
between the two adjuvants. Therefore, all animals from both
adjuvant + BG505 SOSIP groups were pooled together for all
subsequent analyses. Seven of 12 animals developed peak titers
of R 1:50. Four animals generated BG505 nAb titers > 1:200
(defined here as top neutralizers). These are the best autologous
tier 2 nAb responses yet reported for HIV Env protein-immunized
NHPs. Based on the results of nAb passive transfer studies,
we infer that these nAb titers may be sufficient for protection
against an autologous tier 2 virus, but this remains to be tested.
The animals in this study were not challenged because the study
was designed as an immunogenicity study, and necropsy
tissues were required for full characterization of the anti-Env
vaccine-elicited responses.
Env-Binding Antibodies
Substantial BG505 SOSIP-binding IgG endpoint titers were
detected by ELISA for all BG505 SOSIP.v5.2-immunized animals
(Figures 1C and S1B). Thus, the difference between RMs that
did or did not develop HIV-neutralizing antibodies in response
to BG505 SOSIP.v5.2 protein immunization was not that the
immunogen was inherently immunological silent in some ani-
mals. Therefore, the immunological process limiting nAb re-
sponses to Env trimers was unknown. We then examined this
knowledge gap.
Longitudinal analyses revealed that the BG505 SOSIP-binding
immunoglobulin G (IgG) responses in plasma after the priming
immunizationwereminimal (Figure 1C). This is a common feature
of protein immunizations in large animals and humans (Evans
et al., 2001; McElrath et al., 2000; West, 1989) and has been pre-
viously observed for BG505 SOSIP (Sanders et al., 2015). BG505
SOSIP-binding IgG in plasma increased substantially after the
second immunization and after the third and fourth immuniza-
tions (Figure 1C). Peak titers did not differ statistically between
the two adjuvant groups (Figure S1B).
BG505 nAb titers did not correlate with BG505 SOSIP-
binding IgG after BG505.v5.2 immunization (Figure 1D). Addi-
tionally, tier 2 nAbs were not detected to heterologous clade A
strains (Experimental Procedures). The observation that BG505
SOSIP-binding IgG titers were not predictive of autologous
BG505 nAb titers indicated that the BG505 SOSIP-binding IgG
was composed of antibody responses to a mixture of neutral-
izing and non-neutralizing epitopes in ratios that are variable
from one animal to another. Non-neutralizing Abs can bind the
exposed base of the trimer, the V3 loop tip, CD4i sites, or
gp120 breakdown products. Anti-V3 antibody responses can
be an immunodominant yet irrelevant response to Env immuni-
zation or HIV infection (Mascola et al., 1996; Mascola and
Montefiori, 2010; McGuire et al., 2014). One aspect of BG505
SOSIP.v5.2 protein design was the modification of the BG505
SOSIP.664 V3 region to reduce exposure of the V3 loop in vitro
(de Taeye et al., 2015). A BG505 V3 peptide ELISA was per-
formed to detect V3 loop-specific IgG in BG505 SOSIP.v5.2-
immunized RMs. The BG505 SOSIP.v5.2 modifications did not
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Figure 1. Generation of Autologous Neutralizing Antibodies by Immunization with BG505 SOSIP.v5.2
(A) Schematic timeline of the BG505 SOSIP.v5.2 immunization study. Nx, necropsy.
(B) BG505 (N332) nAb titers, week 20. Shown is the average from two independent assays. Different adjuvants are indicated by blue and red.
(C) BG505 Env ELISA titers. Vertical lines indicate immunization dates.
(D) BG505 neutralization titers (week 20) compared with BG505 trimer-binding IgG titers (week 20).
(E) BG505 neutralization titers compared with tier 1 neutralization titers of SF162 (left) or MN.3 (right).
(F) Ratio of BG505 trimer binding titers to V3 peptide titers 2 weeks after the third or fourth immunization.
See also Figure S1 and Table S1.eliminate the immunization-induced antibody response to the
BG505 V3 loop (Figure S1C), suggesting that the V3 loop
becomes exposed in vivo during natural protein breakdown
processes (Hu et al., 2015). Because the V3 loop is a major
target of irrelevant tier 1 nAb responses (Mascola et al., 1996;Mo¨rner et al., 2009; Sanders et al., 2013), tier 1 nAb responses
were measured. Autologous BG505 tier 2 nAb titers in BG505
SOSIP.v5.2-immunized RMs did not correlate with tier 1 nAb
titers to MN.3 and SF162 pseudoviruses (Figure 1E), indicating
that HIV Env trimer immunization-elicited neutralizing antibodiesCell Reports 17, 2195–2209, November 22, 2016 2197
against tier 1 and tier 2 viruses are unrelated. The V3 loop Ab
response correlated with the tier 1 MN.3 nAb response, consis-
tent with the V3 loop being in an open confirmation on tier 1 HIV
strain pseudoviruses (r = 0.64, p = 0.03; Figure S1D). Interest-
ingly, the V3 loop responses plateaued after the second immuni-
zation, whereas total BG505 SOSIP IgG continued to increase,
resulting in a higher ratio of SOSIP ELISA- to V3 loop ELISA-spe-
cificAbs after the fourth versus the third immunization (Figure 1F).
In summary, serology showed that a range of autologous nAb
responses were generated by BG505 SOSIP.v5.2 immunization,
including animals with high autologous tier 2 nAb titers and ani-
mals with undetectable autologous nAb, without correlation to
the overall magnitude of the anti-Env IgG response. Therefore,
what was the immunological basis for the qualitatively different
response by nAb responders and non-responders? We consid-
ered that understanding GC and Tfh cell responses within the
draining lymph nodes (LNs) may be critical to assess the immu-
nological processes responsible for generating immunization-
elicited HIV tier 2-neutralizing antibodies.
Fine Needle Aspirates Quantitatively Monitor Germinal
Center Activity in Draining Lymph Nodes
GC B cells and GC Tfh cells are not present in blood and, there-
fore, can only be studied with lymphoid tissue samples. Whole
LN excision has been rarely performed in human vaccine
studies. Whole LN excisional biopsies can be performed as
part of vaccine studies in NHPs; however, removal of a draining
LNs has numerous drawbacks and can only be done once, thus
precluding longitudinal assessment of the vaccine-induced
GC responses. This inability to directly quantify GC activity (GC
B cells and GC Tfh cells) in response to an immunization has re-
mained a vexing ‘‘black box’’ problem for vaccine immunology of
monkeys and humans. Therefore, we used fine needle aspirates
(FNAs) of the draining LNs to sample GCB cells andGC Tfh cells.
The LN fine needle aspiration technique is widely used in clinical
oncology for non-quantitative diagnostic purposes as a simple
outpatient procedure (Diamantis et al., 2009). Importantly, longi-
tudinal FNAs could theoretically be used to monitor GC cells
within the same LN of the same animal after each immunization.
However, because LN FNAs have only rarely been used for vac-
cine studies, several issues needed to be addressed. Can FNAs
provide enough cells to gain immunologically useful information?
Do repeated fine needle aspirations interfere with the GC or anti-
body responses? Are the GC B cell and GC Tfh cell populations
obtained by FNA sampling representative of those in the whole
LN? Each of these questions affects the potential value of LN
FNA sampling.
To address these issues, a pilot LN FNA study was conducted
in a group of uninfected and SHIV-infected RMs at necropsy
(Figure S2A). The frequencies of both GCB cells (p < 0.0001; Fig-
ure S2B) and GC Tfh cells (p < 0.0001; Figure S2C) correlated
with the respective cell frequencies in the matched whole LNs.
These results supported the potential utility of LN FNAs in NHP
vaccine studies. LN fine needle aspirations were then performed
on eight of the 12 BG505 SOSIP.v5.2-immunized RMs 3 weeks
after each immunization, with the remaining four animals left
without LN fine needle aspirations as a control. The average
cell yield per LN fine needle aspiration was13 106 (Figure 2A).2198 Cell Reports 17, 2195–2209, November 22, 2016The vast majority of FNAs provided >1 3 105 cells (95%, 91 of
96), sufficient for flow cytometric analysis of GC Tfh cells and
GC B cells (Figure 2B). One issue to address was whether the
LN fine needle aspiration procedure might affect immune re-
sponses. Although we considered this unlikely, because only
106 cells are removed and LN fine needle aspirations are well
tolerated in humans, it was nevertheless important to investi-
gate. After the final immunization, whole lymph node biopsies
were taken from animals that did or did not undergo serial
LN fine needle aspirations (Figure 2C). Neither the frequency of
GC B cells nor GC Tfh cells was affected by the serial LN fine
needle aspirations (Figures 2D and 2E). Furthermore, antibody
titers did not differ between the animals that did or did not
undergo serial LN fine needle aspirations (Figure 2F).
Finally, we askedwhether LN FNA sampleswere quantitatively
representative of the LN GC B cell and GC Tfh cell frequencies.
Twenty-four pairs of FNA and whole LN biopsies from BG505
SOSIP.v5.2-immunized animals were analyzed (Figure 2C,
group 3). A LN fine needle aspiration was performed, and then
the same LNwas immediately removed for analysis. On average,
FNA samples represented 3.1% of the cellularity of whole LNs
(Figure 2G). The frequency of GC B cells among total CD20+
B cells in the LN FNAs correlated strongly with the GC B cell fre-
quency in the whole LN biopsy (r = 0.79, p < 0.0001; Figure 2H).
The frequency of GC Tfh cells also correlated strongly (r = 0.66,
p < 0.0005; Figure 2I). In sum, FNAs of draining LNs after vacci-
nation provided sufficient cells for immunological analysis, was
non-disruptive to the antibody and GC responses, and properly
quantified GC B and GC Tfh cell populations within an LN.
Massive Germinal Center Responses to Priming Protein
Immunization
A priming immunization with a protein antigen is generally
considered a small immunological event in humans and large
animal models (Evans et al., 2001; McElrath et al., 2000; West,
1989), unlike in mice. Antibody titers in the plasma are minimally
elevated after an initial immunization (Figure 1C; Sanders et al.,
2015). In addition, CD4 T cell responses in the blood after protein
immunizations are generally undetectable or barely detectable
(McElrath et al., 2000; Verschoor et al., 1999). However, very little
is directly known about the magnitude of the CD4 T cell and
B cell responses at the primary site of the immune response
to a protein immunization in monkeys or humans. Thus, GC re-
sponses were examined in RMs immunized once with BG505
SOSIP.v5.2. GC Tfh cells were dramatically increased in the
protein + adjuvant immunization groups 21 days after the
priming immunization (unimmunized versus adjuvant + BG505
SOSIP.v5.2, p = 0.0001), with mean GC Tfh cell frequencies of
7.3% of total CD4 T cells, respectively (Figures 3A and S3A).
The frequencies of GC B cells were vastly increased in the
protein + adjuvant immunization groups (unimmunized versus
adjuvant + BG505 SOSIP.v5.2, p = 0.0001; Figure 3B). On
average, GC B cell frequencies of 20.2% were observed in
draining LNs after a single immunization. That is vastly higher
than in protein-immunized mice (3% or lower) (Hu et al., 2015;
Kuraoka et al., 2016). The frequency of GC B and GC Tfh cells
in immunized RMs strongly correlated in the primary immune
response (r = 0.86, p < 0.0001; Figure 3C), consistent with the
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Figure 2. FNAs Monitor GC Activity in Draining Lymph Nodes
(A) Cell recovery from LN FNAs (n = 24). Error bars show 95% confidence intervals.
(B) Flow cytometry from LN FNA samples gated on GC B cells among CD20+ B cells (left) or GC Tfh cells among CD4+ T cells (right).
(C) Experimental group design. Bx, whole LN biopsy.
(D) GC B cell frequency in whole LN biopsies 3 weeks after the fourth immunization (n = 12/group). LNs were either previously sampled by FNA (group 1) or not
(group 2).
(E) GC Tfh cell frequency in whole LN biopsies 3 weeks after the fourth immunization (n = 12/group). LNs were either previously sampled by FNA (group 1) or not
(group 2).
(F) BG505 SOSIP.v5.2 ELISA titers at week 0 and week 14 for animals that had undergone previous LN FNAs (group 1) or not (group 2).
(G) Percentage of cells sampled per LN by FNA (n = 24).
(H) GC B cell frequency determined from FNA or whole LN biopsy (n = 24). Each point represents an individual LN sampled by fine needle aspiration and then by
whole LN biopsy.
(I) GC Tfh cell frequency as in (H).
See also Figure S2.
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See also Figure S3.interdependence of GC B cells and GC Tfh cells (Crotty, 2011;
Johnston et al., 2009; Victora et al., 2010). The ‘‘adjuvant only’’
control group did not differ from the unimmunized group
(Figures 3A and 3B), confirming that the GC responses to the
SOSIP immunization were antigen-specific. In summary, strik-
ingly high frequencies of GC B and GC Tfh cells are induced
in draining LNs of monkeys after a single protein + adjuvant
immunization, discordant from the primary serological response
to the immunogen.
Longitudinal Monitoring of Germinal Center Responses
in Individual LNs during an Immunization Series
Multiple immunizations will likely be required to successfully
generate HIV bnAbs via a vaccine (Burton and Hangartner,
2016; Haynes et al., 2016; Klein et al., 2013). Therefore, booster
immunizations need to generate germinal centers. In mice,
booster immunizations of protein + adjuvant predominantly
induce strong plasmablast responses but can induce some 2
GC responses (Dogan et al., 2009; Pape et al., 2011). The extent
to which secondary GCs occur after immunizations in monkeys
or humans and how the 2 GC response compares with the
1 GC response in the same individual is unknown.
Six weeks after the priming immunization, the first booster im-
munization was given (Figure 1A). As a group, draining LNs from
immunized RMs had statistically higher GC B cell frequencies
than unimmunized RMs (p = 0.03; Figure 4A), whereas there
was a trend for increased GC Tfh cells (p = 0.1; Figure 4B).
Because LN FNA samples were obtained from the same draining
LN sites after each immunization, GC recall responses could be
directly compared with the priming responses. Mean GC B cell
frequencies after the second immunization were only 60% of
the GC B cell frequencies observed after the first immunization
(13.7% versus 22.4%; paired p = 0.006; Figure 4C). Similarly,
mean GC Tfh cell frequencies were only 43% of the GC Tfh2200 Cell Reports 17, 2195–2209, November 22, 2016cell frequencies observed after the first immunization (3.4%
versus 8.0%, paired p = 0.004; Figure 4D). Thus, the second im-
munization generated markedly fewer GC Tfh and GC B cells
than the primary immunization.
After the second immunization, anti-Env plasma antibody
titers increased by a factor of 17 on average (Figure 1C). The
frequency of GC B cells and GC Tfh cells after the first immuni-
zation exhibited strong trends for a correlation with the BG505
SOSIP binding titers 2 weeks after the second immunization
(GC B cells: r = 0.62, p = 0.06; GC Tfh cells: r = 0.62, p = 0.06;
Figures 4E and 4F). In addition, Env-specific plasmablasts
were present in the blood 5 days after the second immunization
but not in unimmunized animals (p = 0.001; Figure 4G). Taken
together, robust GC activity induced by the priming immuniza-
tion led to strong plasmablast and Env antibody responses
upon the next immunization.
Diverse patterns of GC activity were observed in individual
animals (Figures 4H and S3D), but overall GC responses after
all booster immunizations tended to be lower than the primary
response. The frequency of GC B and GC Tfh cells correlated
at each individual time point and over all time points (all time
points: r = 0.83, p < 0.0001; Figure S3C). Examination of the
GC responses of the RMs to the third and fourth immunizations
revealed that the mean frequencies of GC B and GC Tfh cells in
the draining LNs were significantly higher than in the unimmu-
nized control group at both time points (Figures 4I and 4J).
To investigate whyGC responses generated by booster immu-
nization may be lower in magnitude than those generated by the
primary immunization, GC responseswere examined 6weeks af-
ter the final immunization. This was chosen to match the interval
between previous immunizations. Substantially elevated fre-
quencies of GC B cells and GC Tfh cells were still present in the
draining LNs 6weeks after the final immunization (GCB cells, un-
immunized versus immunized, 3.5% versus 10.5%, p < 0.0001;
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Figure 4. Longitudinal Monitoring of GC Responses
(A) Frequency of GC B cells in draining LNs 3 weeks after the second immunization (week 9) compared with matched LNs from unimmunized RMs (none).
(B) Frequency of GC Tfh cells as in (A).
(C) Frequency of GC B cells as in (A), with Wilcoxon matched pairs rank test.
(D) Frequency of GC Tfh cells as in (B), with Wilcoxon matched pairs rank test.
(E) GC B cell frequency (draining LNs at week 3, average of left and right inguinal LNs) compared with BG505 binding titers.
(F) GC Tfh cell frequency as in (E).
(legend continued on next page)
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Figure 4K; GC Tfh cells, 1.5% versus 3.0%, p < 0.0001; Fig-
ure S3E). Additional LN FNAs revealed GCs persisting for up to
120 days after immunization (Figure 4K). Therefore, given the
magnitude of the GC responses observed 42 days after the
final immunization, and the magnitude of the GC responses
observed 21 days after each immunization, it is highly likely that
the booster immunizations at 42-day intervals were given in the
face of substantial ongoing GC responses initiated by the previ-
ous immunization. That may have negative consequences.
Env-Specific Tfh Cells in LNs
The intrinsic biology of GC Tfh cells dictates that these cells be
stingy cytokine producers (Dan et al., 2016; Havenar-Daughton
et al., 2016b). This explains why it has been very difficult or
impossible to detect antigen-specific GC Tfh cells by intra-
cellular cytokine staining in most contexts (Hessell et al., 2016;
Havenar-Daughton et al., 2016b), resulting in the impression
that antigen-specific GC Tfh cells are quite rare. We have devel-
oped a cytokine-independent methodology, referred to as the
activation-induced marker (AIM) method (Dan et al., 2016; Have-
nar-Daughton et al., 2016b), for detecting antigen-specific GC
Tfh cells. AIM shows an acceptable background in adjuvant
only-immunized macaques and retains fidelity of the GC Tfh
cell phenotype after stimulation. Strikingly, a median of 6.4%
of GC Tfh cells were Env-specific 21 days after the final Env
trimer immunization (range, 1.3%–39.3%; Figures 5A and 5B).
Env-specific non-Tfh cell responses were also present (Figures
5C and 5D). Together, these data demonstrate surprisingly
robust antigen-specific GC Tfh and non-Tfh CD4 T cell re-
sponses to a protein immunization.
GC B Cells and Autologous nAbs
Directly probing the GCs at the primary site of the immune
response allowed for interrogation of specific immunological
factors potentially predictive of the generation of HIV nAbs.
The strongest immunological feature associated with the devel-
opment of BG505 nAbs was the frequency of GC B cells after
booster immunizations (Figures 6A and 6B). A correlation be-
tween nAbs and the average frequency of GCB cells in response
to the third and fourth immunizations was observed for the eight
serial LN FNA animals that was of borderline statistical signifi-
cance (r = 0.71, p = 0.06; Figure 6A). A wider analysis, including
all animals for which LN samples were available, demonstrated a
strong association between GC B cell activity after the final
(fourth) immunization and the development of nAbs (p = 0.007;
Figure 6B). The median frequency of LN GC B cells in top neu-
tralizers was almost 3-fold higher than in non/low neutralizers
(median GC B cells; top, 20.3% versus non/low, 7.6%; Fig-
ure 6B). Tier 2 nAb development was also associated with GC(G) BG505 Env-specific IgG+ plasmablasts in blood in RMs that did (2nd Imm) or
(H) Longitudinal peak GC B cell frequencies in left (L) and right (R) draining ingu
indicates animals receiving PGLA adjuvant; red indicates animals receiving Iscom
(I) Frequency of GC B cells (left) and GC Tfh cells (right) in draining LNs 3 wee
unimmunized RMs.
(J) As in (I), 3 weeks after the fourth immunization (week 21).
(K) GC B cells in LNs plotted by time since the most recent immunization.
See also Figure S3.
2202 Cell Reports 17, 2195–2209, November 22, 2016B cell frequencies after the second and third immunizations (Fig-
ure 6B). In contrast, neither BG505 SOSIP IgG ELISA binding ti-
ters (p = 0.88; Figure S4A) nor tier 1 nAbs (p = 0.58; Figure S4B)
correlated with GC B cell activity to the later immunizations,
highlighting the specificity of the association between the ability
of the immune system of select animals to re-elicit strong GC
responses to booster immunizations and the development of
a strong autologous tier 2 nAb response. In conclusion, GC B
cell frequencies in draining LNs after the booster immunizations
were strongly associated with successful development of autol-
ogous tier 2 neutralizing antibodies.
Given the large magnitude of the GC responses in the LNs of
top neutralizers, we reasoned that GC B cell clonal lineages
responding to HIV Env may be individually identifiable by next
generation sequencing (NGS) as clusters of closely related
BCR sequences. We sequenced IgM and IgG BCRs from LN
FNA samples using NGS (Figures 6C, 6D and S5). Large to
very large lineages of 50–30,000 independent sequences from
the LNs of Env-immunized animals were readily organizable
into phylogenic trees. We focused the analysis on the top 50
largest lineages per immunized animal (Figures S5B and 6C).
Phylogenetic trees were densely populated with closely related
sequences (Figure 6D), many differing by only a single nucleo-
tide, consistent with expectations for large active GCs, and
also likely including some plasma cell and memory B cell se-
quences. Mutation frequencies per lineage increased over time
during the course of the immunization (p < 0.04; Figures S6D
and S6E). Three of the top 50 largest lineages from one of the
top neutralizers, ROp15, were confirmed to be BG505 trimer-
specific by cross-referencing the NGS lineages against an initial
set of 109 BCR sequences of BG505 SOSIP.v5.2 trimer-binding
B cells isolated from the peripheral blood or spleen at necropsy
(Figures 6D, S5C, and S5F). Based on the large magnitude of
the GC responses in the draining LNs of immunized animals
above that of unimmunized animals (Figure 6B) and animals
receiving adjuvant alone, themajority of B cell lineages observed
in the LN FNA NGS are likely Env-specific, but that awaits future
studies with additional sorts of blood Env-binding B cells.
Analysis of the phylogeny of the largest BG505 SOSIP-specific
lineage (884 independent sequences, see Experimental Pro-
cedures) from ROp15 revealed a number of interesting charac-
teristics. The lineage emerged early in the immune response
(detectable after the first immunization), and BCR sequences
close to the unmutated common ancestor (UCA) were identified
(Figures 6D, S5C, and S5F). The lineage contained interspersed
IgM- and IgG-switched B cells (data not shown). The lineage was
detected after each of the four immunizations. The lineage had
evidence of extensive hypermutation and affinity maturation
over time. Additionally, the lineage was found in both left anddid not receive the second immunization.
inal LNs from individual RMs 3 weeks after each of four immunizations. Blue
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Figure 5. Env-Specific Tfh Responses in LNs
(A) Env-specific GC Tfh cells (CXCR5hi PD-1hi) in draining LNs by AIM assay. CD25+OX40+ cells are gated from the GC Tfh cell population after stimulation
(BG505 Env or SEB) or left unstimulated (). Representative flow cytometry plots are shown.
(B) Env-specific GC Tfh in draining LN 3 weeks after the second, third, and fourth immunizations. The dotted line indicates the positive signal threshold.
(C) Total Env-specific CD4 T cells in draining LNs by AIM assay. CD25+OX40+ cells are gated from total CD4+ T cells after stimulation (BG505 Env or SEB) or left
unstimulated (). Representative flow cytometry plots are shown.
(D) Total Env-specific CD4 T cells in the draining LNs 3 weeks after the second, third, and fourth immunizations. The dotted line indicates the positive signal
threshold.right draining lymph nodes (Figures 6D, S5C, and S5F). Expand-
ing the analysis to the top 50 largest lineages per animal, these
patterns were consistent. LN FNA BCR NGS revealed unmu-
tated common ancestor clones for the majority of the lineages
(Figure S5G). Furthermore, the majority (60%–80%) of lineages
were observed in multiple LN FNA samples (Figure 6C). A
substantial fraction of the lineages were found in both the left
and right draining LNs (26%–66%; Figure 6C). In sum, LN FNA
BCR NGS analysis identified large clonal lineages that could
be traced longitudinally over the course of the immunization
regimen. For BG505 SOSIP-specific sequences from a top
neutralizer, the lineages were detected at the earliest time point,
were detectable at all subsequent time points, were detectable
in both left and right lymph nodes, and exhibited increased mu-
tations over time.
Tfh Cell Quality Is Associated with Autologous nAbs
Tfh cells are not only required for GC reactions to occur but are
also limiting (Johnston et al., 2009; Victora et al., 2010). After the
fourth immunization, which had the strongest association be-
tween GC B cells and nAbs (Figure 6B), the correlation between
GCB cell and GC Tfh frequencies wasmodest (r = 0.53, p = 0.05;
Figure S3A) when compared with the tight relationship between
GC B cells and GC Tfh cell frequencies after the first immuniza-
tion (r = 0.86, p < 0.0001; Figure 3C). This led us to considerwhether the quality of the Tfh cells differed. One way in which
Tfh quality can be conceptualized is the number of GC B cells
supported per GC Tfh cell. The GC B:GC Tfh cell stoichiometry
was more than doubled in top neutralizer RMs compared with
non/low neutralizer RMs (GC B cell to GC Tfh ratio: top, 6.8
versus non/low, 3.1, p = 0.005; Figures 7A, 7B, and S6A; GC B
cell to GC Tfh ratio: top versus low, p = 0.049; top versus non,
p = 0.029; Figure S6B). The increased GC B:GC Tfh cell ratio
suggested that top neutralizers had larger germinal center re-
sponses because their Tfh cells were capable of supporting
larger GC B cell populations.
LN FNA GC Tfh cell numbers were too limiting for additional
analysis. Therefore, we examined whether Env-specific CD4
T cells were detectable in peripheral blood. Substantial fre-
quencies of Env-specific CD4 T cells were detected in the blood
both 1 and 3 weeks after the first immunization (control versus
week 1, p = 0.0017; control versus week 3, p = 0.0017; Figures
7C and 7D). Env-specific CD4 T cell responses were also robust
in the blood after the final immunization, at week 19 (control
versus week 19, median: 0.16% versus 0.92%, p = 0.0018; Fig-
ure 7D) and week 24 (control versus week 24, median: 0.16%
versus 2.4%, p = 0.0003; Figure 7D). Elevated frequencies of
Env-specific CXCR5+ CD4 T cells were also detected in the
blood at the same time points (p < 0.003; Figures S6C and
S6D). To further assess the quality of the CD4 T cell responses,Cell Reports 17, 2195–2209, November 22, 2016 2203
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Figure 6. GC B Cell Relationships to Autologous nAbs and Longitudinal Sequencing Analysis of Clonal Lineages and Affinity Maturation
Identified in LN FNAs of BG505 SOSIP.v5.2-Immunized RMs
(A) GC B cells after the third and fourth immunizations compared with the BG505 neutralization titer. Each point represents the average of four GC B cell
measurements (two draining LNs at two time points) for an individual animal. Longitudinal GC B cell data were only acquired from the eight RMs undergoing FNA
analysis. Neutralizing titers are log-transformed values.
(B) GC B cell frequencies in draining LNs after each immunization for top neutralizers (red) and non/low neutralizers (black). Points represent individual LNs. The
dotted line indicates the mean frequency of GC B cells in unimmunized RM LNs.
(legend continued on next page)
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200–5,000 AIM+ Env-specific CD4 T cells were sorted from
peripheral blood mononuclear cells (PBMCs) after the fourth im-
munization and analyzed byRNA sequencing (RNA-seq) (Figures
S6E and S6F; Table S2). Extensive gene expression differences
were observed between Env-specific CD4 T cells in high neutral-
izers and non-neutralizers (1,012 upregulated, 1,354 downregu-
lated > 2-fold; Figure 7E). Strikingly, Tfh-associated genes were
more highly expressed in top versus non-neutralizers (Figure 7E).
These included the two most critical proteins for Tfh help to B
cells, IL-21 and CD40L. IL21 was one of the most differentially
expressed genes between top neutralizers and non-neutralizers
(8-fold increase; Figure S6G), with a wide range of expression
among low neutralizers. In addition, two prominent proteins in
human Tfh cell development, ICOS and IL-12Rb (Crotty, 2014;
Ma et al., 2009, 2012; Schmitt et al., 2013) were also more highly
expressed in top neutralizers than in non-neutralizers (Fig-
ure S6G). Significantly higher CD40LG, ICOS, and IL12RB1
gene expression was observed when top neutralizers were
compared with the group of non/low-neutralizers (CD40LG, p =
0.036; ICOS, p = 0.017; IL12RB1, p = 0.018; Figure 7F). Thus,
generation of autologous tier 2 nAbs was associated with Tfh
cell quality, as measured by GC B cell to GC Tfh stoichiometry
and Env-specific CD4 T cell gene expression data. Together,
the correlations between autologous tier 2 nAbs, GC B cell fre-
quency, and Tfh cell quality identify GC responses as a central
limiting process for immunization-induced generation of autolo-
gous tier 2 nAbs.
DISCUSSION
Here, we demonstrate the generation of significant titers of autol-
ogous HIV tier 2 nAbs in the majority of BG505 SOSIP.v5.2-
immunized RMs. Although the BG505 nAbs results are the
best reported to date, the observation of nAb responders and
non-responders highlights the difficulties facing HIV vaccine
development. The T and B cell responses of these animals
were intensively interrogated using a suite of innovative tech-
niques, including longitudinal LN FNAs to quantify GC Tfh cells
and GC B cells, longitudinal GC BCR sequencing, antigen-
specific GC Tfh quantitation by AIM, antigen-specific peripheral
blood Tfh quantitation by AIM, and RNA-seq of Env-specific CD4
T cells. GC B cell frequencies in the draining LNs in response to
the final immunization was the most predictive factor for the
development of autologous nAbs, with the top neutralizers hav-
ing 3-fold more responding GC B cells than animals that only
made non-neutralizing Ab responses. Furthermore, the results
indicate that Tfh cell quality is a key factor for the development(C) The top 50 largest clonal lineages from two representative BG505 SOSIP.v5.2-
neutralizer RUj15 (right). Each BCR lineage is a separate horizontal bar. Freq
demarcated. Colors correspond to specific LNs at specific time points. Blue, left i
time (3 weeks to 21 weeks). The color key is shared with (D). Boxes to the right of e
both left and right LNs (dark gray), and lineages with ‘‘winner’’ (increasing freque
90% of all sequence was found after the final immunization, yellow), and ‘‘loser’’
For shared representation between right inguinal lymph node (R-ILN) and left ing
(D) A BG505 HIV Env trimer-specific LN B cell BCR sequence lineage tree from a
sequence, positioned at the top left. 884 sequences (centroids, each shown as
SOSIP.v5.2-binding B cells found in the blood/spleen are indicated by asterisks.
See also Figures S4 and S5.of autologous nAbs. Thus, GCs are limiting for nAb development
in response to immunization with a candidate HIV vaccine immu-
nogen. These results suggest that direct probing of GCs should
be considered as a central immune correlate in HIV vaccine
trials.
HIV-neutralizing epitopes of circulating tier 2 HIV viruses are
difficult epitopes for the B cell response to recognize (Burton
and Hangartner, 2016; Hu et al., 2015; McGuire et al., 2014;
Sanders et al., 2015). For example, immunization with gp120,
which contains the high-mannose patch, does not elicit N332
supersite-specific bnAbs. In HIV infection, autologous nAbs
generally take many months to develop. nAb responses to
SOSIP immunization require three or more immunizations to
develop (de Taeye et al., 2015; Sanders et al., 2015), if at all
(Hu et al., 2015). In contrast, non-neutralizing Ab epitopes,
such as the V3 loop, are easy epitopes for B cells to recognize
and are robustly elicited by any HIV Env construct. In the case
of HIV-1 Env, difficult neutralizing epitopes and easy non-
neutralizing epitopes are on the same immunogen molecule,
and, therefore, B cells recognizing each type of epitope will
compete for the same protein available. Based on the data
here and in the literature, we posit that non-neutralizing B cell
responses such as V3 specificities dominate the early response.
This presents a daunting challenge for Env-specific B cells with
neutralization potential (i.e., targeting Env epitopes for which
neutralization is possible if the antibody has sufficient affinity)
because they are at a significant competitive disadvantage
compared with the Env-specific B cells targeting non-neutral-
izing epitopes. Thus, in this scenario, the factor that distin-
guishes animals that develop nAbs from animals that fail to
develop nAbs may be the capacity of their immune system to
elicit and maintain Env-specific B cells targeting neutralizing
epitopes early on in the immune response even though B cells
targeting neutralizing epitopes are less competitive than high-
affinity (or high-frequency) B cells specific to easy non-neutral-
izing epitopes.
How can B cells with neutralizing specificities but initial low
affinity for the immunogen best be elicited and maintained in
the GC response? Three possibilities are increasing Tfh help,
increasing the number of B cells exposed to the immunogen,
and favoring presentation of neutralizing epitopes over non-
neutralizing epitopes on the immunogen. CD4 T cell help can
be a limiting factor for successful progression of a low-affinity
B cell into GCs in the face of competition from high-affinity
B cells in the context of nitrophenol hapten immunization in
mice (Schwickert et al., 2011). Thus, by extension, early avail-
ability of Tfh cells may be required for successful recruitmentimmunized RMs. LN BCR sequences from top neutralizer RJk15 (left) and non-
uencies of the lineage sequences found in each LN at each time point are
nguinal LN; burgundy, right inguinal LN. Colors progress from light to dark over
ach chart tabulate recurrent lineages in multiple LNs (gray), lineages present in
ncies over subsequent immunizations, orange), ‘‘extreme winner’’ (more than
(decreasing frequencies over subsequent immunizations, purple) distributions.
uinal lymph node (L-ILN), a cutoff of 1% was used.
top neutralizer animal, ROp15. The tree is rooted to the most related germline
a branch) are shown. The closest branches to the sequences of the BG505
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Figure 7. GC Tfh Cell Quality Is Associated with Autologous nAb
(A) GCB cell:GC Tfh cell ratio in top neutralizers (red) versus non/low neutralizers (black) after the fourth immunization. Each point represents an individual LN. The
best-fit linear correlations were constrained to pass through the origin. The slopes (m) for each line were found to be significantly different (F test, p = 0.0076).
(B) Quantitation of the GC B cell to GC Tfh cell ratio after the fourth immunization from RM neutralizer groups. Points represent individual LNs, and bars indicate
medians.
(C) Representative flow cytometry plots of AIM+ (CD25+ Ox-40+) Env-specific CD4 T cells in PBMCs 1 week after the fourth immunization.
(D) Quantitation of Env-specific CD4 T cell responses in PBMCs of immunized RMs. Cells from unimmunized RMs were used as controls.
(E) RNA-seq analysis of Env-specific CD4 T cells, comparing gene expression of top neutralizer and non-neutralizer RMs. Four Tfh-associated genes are
highlighted (CD40LG, IL21, ICOS, and IL12RB1).
(F) RNA-seq counts of genes of interest from Env-specific CD4 T cells. Top and non/low neutralizing groups are shown. Four Tfh-associated genes (CD40LG,
IL21, ICOS, and IL-12Rb1) and a control gene (YWHAZ) are shown. Bars indicate median values. Average counts are plotted for samples where the RNA-seqwas
repeated. One-way Mann-Whitney p values are shown.
See also Figure S6 and Table S2.of low-affinity HIV Env-specific B cells with nAb potential.
The data presented here indicate a role for Tfh cells in the
development of vaccine-elicited HIV nAbs. Therefore, methods
of inducing additional Tfh cells could be useful (Locci et al.,2206 Cell Reports 17, 2195–2209, November 22, 20162016), or enhancing the quality of the Tfh cells. Second, if B cells
with neutralizing specificities are rare, then engaging larger
numbers of B cells could increase the likelihood of stimulating
an nAb B cell lineage. Diverse GC responses were observed in
the right and left draining LNs of the same animal after bilateral
immunizations, implying a stochastic element to the response
and highlighting the potential value of immunizing at two sites
to increase the number of responding B and T cells. A third
mechanism by which B cells with neutralizing specificities could
be favored may be minimizing the presentation of non-neutral-
izing epitopes. To this end, designs to stabilize Env trimers (de
Taeye et al., 2015; Guenaga et al., 2015) or protect the immu-
nogen via slow release mechanisms (Hu et al., 2015; Tam
et al., 2016) are of interest. One potential metric for assessing
the relative neutralizing and non-neutralizing Ab responses is
the BG505-specific:V3-specific IgG ratio. However, this ratio
did not correlate with neutralization, likely because of the pres-
ence of other non-neutralizing epitopes present on the trimer
(Hu et al., 2015). A shift in the ratio of BG505-specific:V3-specific
IgG when immunizing with BG505.v5.2 was observed, sug-
gesting that BG505 SOSIP.v5.2 partially limits V3 loop immuno-
genicity, which may shift the immunodominance profile of the
B cell response.
GC B cell sequencing data indicate that memory B cells
actively re-circulated after each immunization and reseeded
new GCs. The phylogeny structures suggest that the seeding
of new GCs by memory B cells was likely to come not from the
most mutated branches of the lineage but, instead, from moder-
ately mutated subclones. This is consistent with cross-sectional
data from mouse immunizations with model antigens (Kaji et al.,
2012), suggesting a certain stochasticism to both the GC
response (Tas et al., 2016) and the recall of memory B cell clones
for reseeding new GCs and perhaps a bias toward recall of less
mutatedmemory B cells. Intriguingly, for a top neutralizer animal,
the largest lineages contained more BCR sequences from later
time points, consistent with initially subdominant responses
(i.e., lineages with neutralizing potential) becoming more domi-
nant in top neutralizer animals over time.
LN FNAs provided a powerful technique for the identification
and quantitation of GC B and GC Tfh cells and for longitudinal
GC analysis in each animal. FNA LNs in humans were previously
shown to be non-disruptive to the LN architecture (Prasad et al.,
1996). We expanded on the recent experimental use of LN FNAs
in NHPs that identified GC Tfh cells at steady state (Xu et al.,
2013) and LN FNA analysis in humans where total CD4 T cells
responses were measured after immunization (Tatovic et al.,
2015). We demonstrated that GC B cells are identifiable in LN
FNAs, that GC Tfh cells and GC B cells are quantitatively repre-
sented in LN FNAs, that vaccine-specific GC Tfh cells could be
quantitated in LN FNAs, and that clonal expansion and sequence
evolution of antigen-specific B cell responses can be tracked
longitudinally in fine detail in LN FNAs.
Unexpectedly, robust GC B and GC Tfh cell populations
were induced in the draining LNs of NHPs after a single protein +
adjuvant immunization even while minimal circulating Ab was
generated. Also unexpectedly, the second immunization yielded
significantly lower frequencies of GC cells than the first immuni-
zation. Given the magnitude and longevity of the GC responses
observed, the short interval between immunizations appeared to
have contributed to impairing the GC response to the booster
immunization. Why poor GC boosting occurred at the shorter in-
terval is unknown. One possibility is that new GC reactions mayquench existing germinal centers (McHeyzer-Williams et al.,
2015), prematurely terminating SHM and causing some cost to
the initiation of new germinal centers.
Somatic hypermutation increased in the major GC B cell
lineages upon each successive immunization in this study. A
recent gp140 HIV Env immunization study did not find an asso-
ciation between somatic hypermutation and different adjuvant
groups (Francica et al., 2015). However, no tier 2 nAbs were
elicited in any animals in that study, only non-neutralizing anti-
bodies. Thus, we speculate that only ‘‘easy’’ non-neutralizing/
tier 1A B cell responses were elicited by that immunogen,
which rapidly plateaued in affinity. In contrast, here, develop-
ment of autologous tier 2 nAbs was observed in the majority
of the animals immunized with BG505.v5.2, and major GC
B cell lineages did evolve extensively during the course of the
immunizations.
Understanding the GC response by directly accessing and
interrogating GC cells may be particularly important in upcoming
human phase I clinical trials that will test immunogens that are
not expected in and of themselves to immediately generate
HIV bnAbs but are designed to be important initial steps on a
path to bnAb development (Jardine et al., 2016). Our findings
indicate that GC Tfh cell and GC B cell magnitude and quality
are likely to be central for the success of those approaches
and should be examined directly or by surrogate indicators.
The findings and approaches reported here are also likely
to be valuable for vaccine development to other high-priority
pathogens.
EXPERIMENTAL PROCEDURES
A detailed description of the experimental methods, procedures, flow cytom-
etry panels (Table S3), and associated references is available in the Supple-
mental Experimental Procedures.
Statistics
The Mann-Whitney test was used for evaluating differences among groups.
The Wilcoxon test was used to evaluate differences between samples ob-
tained at different time points from the same animal unless otherwise noted.
The Spearman correlation test was used for correlative analysis unless other-
wise noted. Prism 6.0 (GraphPad) was used for all statistical analyses.
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